Related trials
RE-NOVATE 2, 2010 - dabigatran 220mg vs enoxaparin
ADVANCE 2 (CV185-047), 2010 - apixaban vs enoxaparin
WATCH (warfarin vs aspirin), 2009 - warfarin vs aspirin
RECORD 4, 2009 - rivaroxaban vs enoxaparin
RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin
RECORD 3, 2008 - rivaroxaban vs enoxaparin
RECORD 2, 2008 - extended rivaroxaban vs enoxaparin
RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin
ADVANCE-1, 2008 - apixaban vs enoxaparin
RECORD 1, 2008 - extended rivaroxaban vs extended enoxaparin
RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin
RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin
RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin
RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin
HELAS (warfarin vs aspirin), 2006 - warfarin vs aspirin
ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin
HELAS (warfarin vs placebo), 2006 - warfarin vs placebo
ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin
BISTRO II (225mg bid), 2005 - dabigatran 450mg vs enoxaparin
NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 - triflusal+coumadin medium dose vs triflusal
NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 - triflusal+coumadin medium dose vs coumadin standard dose
WASH (aspirin), 2004 - aspirin vs no treatment
WASH (warfarin), 2004 - warfarin vs no treatment
PATAF (coumadin low dose vs coumadin standard dose), 1999 - coumadin low dose vs coumadin standard dose
AFASAK II (warfarin low dose vs warfarin standard dose), 1998 - warfarin low dose vs warfarin standard dose
See also:
All heart failure clinical trials
All clinical trials of antithrombotics
All clinical trials of warfarin
|
|
Treatments
Studied treatment |
warfarin (target INR 2.5-3.0)
|
Control treatment |
aspirin 162 mg daily
|
Patients
Patients |
symptomatic heart failure patients in sinus rhythm with ejection fractions 35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics |
Method and design
Randomized effectives |
540 / 523 (studied vs. control) |
Design |
Parallel groups |
Blinding |
open |
Primary endpoint |
death from all causes, nonfatal |
Results
No results available for this trial
- no clinical endpoint reported
Meta-analysis of all similar trials:
antithrombotics in heart failure for all type of patients
Reference(s)
-
Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S, .
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics..
J Card Fail 2004;10:101-12.
Pubmed
|
Hubmed
| Fulltext
-
Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR.
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial..
Circulation 2009 Mar 31;119:1616-24
Pubmed
|
Hubmed
| Fulltext
|